// App-Quantinova.ai

2512 : Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.

Researchers

Presenter

  • Emma Jane Dean

Principal Investigators

  • Gerald Steven Falchook

  • Manish R. Patel

  • Andrew Jacob Brenner

  • Jeffrey R. Infante

  • Hendrik-Tobias Arkenau

  • Erkut Hasan Borazanci

  • Juanita Suzanne Lopez

  • Shubham Pant

  • Peter Schmid

  • Arthur E. Frankel

  • Suzanne Fields Jones

  • William McCulloch

  • George Kemble

  • Marie O'Farrell

  • Howard Burris

Medical Centers

  • University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

  • Sarah Cannon Research Institute, Denver, CO

  • Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • Sarah Cannon Research Institute, Nashville, TN

  • Sarah Cannon Research Institute UK, London and University College London Hospitals., London, United Kingdom

  • Virginia G. Piper Cancer Center, TGen, Scottsdale, AZ

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Oklahoma University Health Science Center, Edmond, OK

  • University of Sussex, London, United Kingdom

  • The University of Texas Southwestern, Dallas, TX

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Alba BioPharm Advisors Inc, Raleigh, NC

  • 3-V Biosciences Inc, Menlo Park, CA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Paclitaxel

  • TVB2640

Outcome

  • N/A

Study Design

  • Multicenteric

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02223247

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved